Thx for the hint, Lectroid. Even after some hours of thought I...

Thx for the hint, Lectroid. Even after some hours of thought I can not point to a single reason from yesterday’s HY report as to why to sell such an enormous amount of shares at such a huge discount vs market close.

US$157M in cash by Dec 31, 2023 should mean appr. US$80M in cash left by Jun 30, 2024. Which means OPT being financed pretty exactly through YE2024 if they were to run down cash to the very last dime. Which they won‘t of course…

We can say for sure that OPT has to refinance by late Aug 2024 in order to get the green light regarding going concern in the FY2024 annual report.
The minimum net amount of this next refinancing will have to provide sufficient cash resources for the 12 months post the issuance of the FY2024 financial statement (due Aug 31, 2024), so through Aug 31, 2025.

Those minimum net proceeds needed would be appr. US$100M. Again, just to get the going concern green light in the next FY2024 financial statement.

US$100M net via a share issuance would be some US$110M gross.
If we take the 195M shares OPT issued during the last raise in Aug 2023, that would correspond to an issuance price of appr. 90c.
Or alternatively 220M shares (25% dilution) for appr. 80c.

Or again alternatively and maybe even better, getting a regional partnership done, the kind of which OPT alludes to pretty explicitly in the HY report:

“A key objective of the company over the next 12 months is to prepare for various opportunities to advance further development and commercialization of sozinibercept through engagement with pharmaceutical/biotechnology companies.“